Gemeinschaft and Gesellschaft

Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan

Retrieved on: 
Friday, February 16, 2024

TOKYO, Feb 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate).

Key Points: 
  • TOKYO, Feb 16, 2024 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the additional formulation of Metoject Subcutaneous Injection for the anti-rheumatic agent, pen-type autoinjector "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate).
  • Based on the license agreement signed by Eisai and medac GmbH in May 2019, nippon medac will hold the marketing authorization of Metoject, while Eisai will be responsible for product distribution of Metoject in Japan.
  • This formulation incorporates the previously MHLW-approved Metoject Subcutaneous Injection pre-filled syringe formulation in a pen-type autoinjector and was developed to reduce the burden on patients and improve safety during self-injection.
  • The drug can be self-injected in two steps (1- removing the cap, 2- pressing the pen against the skin).

China Medical System: NDA for Additional RA Indication of Methotrexate Injection Accepted in China

Retrieved on: 
Monday, December 4, 2023

The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new milestone following the China approval for psoriasis indication of Methotrexate Injection.

Key Points: 
  • The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new milestone following the China approval for psoriasis indication of Methotrexate Injection.
  • The Product is expected to become the first methotrexate (MTX) prefilled injection to treat RA by subcutaneous administration in China.
  • China Medical System Holdings Limited ( “CMS” or the “Group”) announced that on 4 December 2023, the New Drug Application (NDA) for an additional indication of its innovative product, Methotrexate Injection (the “Product”), has been accepted by the National Medical Products Administration of China (NMPA).
  • The Product is a small-volume methotrexate injection with various strengths, which is intended to be used to treat active rheumatoid arthritis (RA) in adult patients.

Tracing the Steps of Medieval Writers

Retrieved on: 
Monday, December 12, 2022

ST. PÖLTEN, Austria, Dec. 12, 2022 /PRNewswire/ --  So far, traditional manual writing style analysis has been carried out by experts in a tedious and time-consuming process.

Key Points: 
  • ST. PLTEN, Austria, Dec. 12, 2022 /PRNewswire/ -- So far, traditional manual writing style analysis has been carried out by experts in a tedious and time-consuming process.
  • "There are approaches to identifying the manuscripts of medieval scribes with the help of machine learning.
  • "This project does not just help us to interactively work on a significant desideratum of historical research.
  • It also creates new possibilities and tools of analysis that enable a deeper knowledge of all other medieval scriptoria in the area that is now Lower Austria.

Tracing the Steps of Medieval Writers

Retrieved on: 
Monday, December 12, 2022

ST. PÖLTEN, Austria, Dec. 12, 2022 /PRNewswire/ --  So far, traditional manual writing style analysis has been carried out by experts in a tedious and time-consuming process.

Key Points: 
  • ST. PLTEN, Austria, Dec. 12, 2022 /PRNewswire/ -- So far, traditional manual writing style analysis has been carried out by experts in a tedious and time-consuming process.
  • "There are approaches to identifying the manuscripts of medieval scribes with the help of machine learning.
  • "This project does not just help us to interactively work on a significant desideratum of historical research.
  • It also creates new possibilities and tools of analysis that enable a deeper knowledge of all other medieval scriptoria in the area that is now Lower Austria.

Metoject Subcutaneous Injection Syringe (Methotrexate) Launched In Japan For Rheumatoid Arthritis

Retrieved on: 
Wednesday, November 16, 2022

TOKYO, Nov 16, 2022 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg syringe 0.15mL, 10mg syringe 0.20mL, 12.5mg syringe 0.25mL and 15mg syringe 0.30mL" (methotrexate, "MTX") in Japan with the indication of rheumatoid arthritis.

Key Points: 
  • TOKYO, Nov 16, 2022 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg syringe 0.15mL, 10mg syringe 0.20mL, 12.5mg syringe 0.25mL and 15mg syringe 0.30mL" (methotrexate, "MTX") in Japan with the indication of rheumatoid arthritis.
  • nippon medac obtained the manufacturing and marketing approval of Japan's first self-administrable subcutaneous injection formulation of MTX, a first line option for the treatment of rheumatoid arthritis, on September 26, 2022.
  • "Eisai has established a solid franchise and has extensive sales experience in the rheumatoid arthritis area in Japan.
  • It is also the first self-administrable MTX subcutaneous injection formulation for rheumatoid arthritis in Japan," said Hirohisa Iriyama, Representative Director and President of nippon medac.

Addex Increases Issued Share Capital to Create Treasury Shares

Retrieved on: 
Tuesday, November 1, 2022

The new shares, issued from the Companys authorized capital, are listed on the SIX Swiss Exchange.

Key Points: 
  • The new shares, issued from the Companys authorized capital, are listed on the SIX Swiss Exchange.
  • The total number of issued shares increased to 97,909,428 at a nominal value of CHF 0.01 each, whilst the outstanding shares remain unchanged.
  • 135 FMIA in respect of all listed shares of Addex Therapeutics Ltd in connection with the transaction described in this decision.
  • Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange.

EQS-News: splendid medien AG: Stefan Sporn wird COO der Splendid Medien AG und Geschäftsführer der Splendid Synchron GmbH

Retrieved on: 
Friday, October 28, 2022

November 2022 wird Prof. Dr. Stefan Sporn Chief Operating Officer (COO) der Splendid Medien AG.

Key Points: 
  • November 2022 wird Prof. Dr. Stefan Sporn Chief Operating Officer (COO) der Splendid Medien AG.
  • Gleichzeitig bernimmt er neben Sonja Claus die Geschftsfhrung der Splendid Synchron GmbH, 100%iges Tochterunternehmen der Splendid Medien AG, Kln.
  • Stefan Sporn folgt bei der Splendid Synchron auf Oliver Fay und Dr. Dirk Schweitzer, die zum 1.November 2022 aus der Geschftsfhrung der Splendid Synchron ausscheiden.
  • Dr. Dirk Schweitzer, Vorstandsvorsitzender der Splendid Medien AG: Mit Stefan Sporn haben wir einen ausgezeichnet vernetzten und auch international sehr erfahrenen Medienmanager fr verschiedene Aufgaben des Konzerns und die Geschftsfhrung der Splendid Synchron gewinnen knnen.

Eisai: Metoject Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheumatoid Arthritis

Retrieved on: 
Monday, September 26, 2022

Metoject will be the first self-administrable MTX subcutaneous injection formulation for rheumatoid arthritis in Japan.

Key Points: 
  • Metoject will be the first self-administrable MTX subcutaneous injection formulation for rheumatoid arthritis in Japan.
  • It is reported that there are approximately 700,000 - 800,000 rheumatoid arthritis patients in Japan.
  • Eisai and nippon medac will provide a self-administrable subcutaneous injection as a new treatment option for rheumatoid arthritis patients in Japan as soon as possible, and will make further contributions to address the diversified needs of, and increase the benefits provided to, rheumatoid arthritis patients.
  • *ACR20 is a criterion developed by the American College of Rheumatology that measures improvement in clinical symptoms of rheumatoid arthritis.

DGAP-News: Clean Logistics SE: Jürgen Akkermann appointed as CFO of Clean Logistics

Retrieved on: 
Monday, September 12, 2022

Hamburg, 12 September 2022: Clean Logistics SE (ISIN DE000A1YDAZ7) is expanding its executive management in line with its dynamic growth and has appointed Jrgen Akkermann as Chief Financial Officer (CFO).

Key Points: 
  • Hamburg, 12 September 2022: Clean Logistics SE (ISIN DE000A1YDAZ7) is expanding its executive management in line with its dynamic growth and has appointed Jrgen Akkermann as Chief Financial Officer (CFO).
  • As CFO, the holder of a degree in business administration, will be in charge of finance and ESG at Clean Logistics.
  • Dirk Graszt, CEO of Clean Logistics: "We are pleased to welcome Jrgen Akkermann and Fraser R. McKenzie, two seasoned financial experts, to Clean Logistics.
  • By continuously upgrading its product portfolio, Clean Logistics SE sustainably strengthens the marketability of its innovative, safe and durable solutions.